Search

Displaying results 3371 - 3380 of 10000 in total
  1. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development. … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

  2. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. … It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus.

  3. Drug

    Bordetella pertussis toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14388
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.

    Mixtures: TETRAXIM 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
  4. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    Frespaciguat is under investigation in clinical trial NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With … Frespaciguat has a monoisotopic molecular weight of 608.14 Da.

  5. Drug

    Gancotamab

    go.drugbank.com/drugs/DB14784
    Investigational

    Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. … Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).

  6. Drug

    Belapectin

    go.drugbank.com/drugs/DB15125
    Investigational

    Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).

  7. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses. … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand

  8. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    protein expression in cell culture. … ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  9. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.

  10. Drug

    Farletuzumab ecteribulin

    go.drugbank.com/drugs/DB18857
    Investigational

    Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), … a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).